| Drug ID: | Drug67 |
|---|---|
| Drug Name: | 2'-Fucosyllactose |
| CID: | 170484 |
| DrugBank ID: | DB16052 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT03847467 |
| Molecular Formula: | C18H32O15 |
| Molecular Weight: | 488.4 g/mol |
| Isomeric SMILES: | C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)CO)O)O)O)O)O |
| Synonyms: | 2'-Fucosyllactose; 41263-94-9; 2'-O-fucosyllactose; Lactose, 2'-o-fucosyl-; 2'-o-l-fucosyl-d-lactose; XO2533XO8R; UNII-XO2533XO8R; DTXSID40194179; D-Glucose, O-6-deoxy-alpha-L-galactopyranosyl-(1-2)-O-beta-D-galactopyranosyl-(1-4)-; (2R,3R,4R,5R)-4-{[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-2,3,5,6-tetrahydroxyhexanal |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05266287 | Changes in Microbiota and Quality of Life in IBS | NA | UNKNOWN | National University of Natural Medicine | IBS - Irritable Bowel Syndrome | DIETARY_SUPPLEMENT: a supplement containing 2'-fu… | Details |
| NCT03847467 | Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy | PHASE1|PHASE2 | RECRUITING | Children's Hospital Medical Center, Cincinnati | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | DRUG: 2'-Fucosyllactose|OTHER: Placebo | Details |
| NCT06050811 | Prebiotics in Reducing Inflammation and Clinical Endpoints in Ulcerative Colitis (PRInCE-UC) | NA | COMPLETED | Royal Berkshire NHS Foundation Trust | Ulcerative Colitis | DIETARY_SUPPLEMENT: 2'-Fucosyllactose|DIETARY_SUP… | Details |
| NCT05687474 | Baby Detect : Genomic Newborn Screening | NULL | COMPLETED | Centre Hospitalier Universitaire de Liege | Congenital Adrenal Hyperplasia|Familial Hyperinsu… | None | Details |
| NCT05120752 | Efficacy of a Low FODMAP Diet in the Absence of Lactose Malabsorption in Moderate to Severe ROME IV IBS. | PHASE3 | RECRUITING | Universitair Ziekenhuis Brussel | Irritable Bowel Syndrome | OTHER: FODMAP diet | Details |
| NCT05100719 | The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) | NA | NOT_YET_RECRUITING | University of Pecs | Irritable Bowel Syndrome|Lactose Intolerance|Lact… | DRUG: alverine-citrate + simethicone and lactase|… | Details |
| NCT05001997 | Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome | NA | UNKNOWN | University of Central Lancashire | Irritable Bowel Syndrome | DIETARY_SUPPLEMENT: Lactose free probiotic yogurt | Details |
| NCT04974593 | Predictive Value of Hydrogen/Methane Lactose Breath Testing on the Therapeutic Effect of Lactose-free Diet in Moderate to Severe ROME IV IBS. | PHASE3 | RECRUITING | Universitair Ziekenhuis Brussel | Irritable Bowel Syndrome|Lactose Intolerant | OTHER: low fat diet | Details |
| NCT04543474 | Treatment Efficacy of Low FODMAP Versus Low Lactose Diet in IBS Patients | NA | COMPLETED | Cantonal Hospital of St. Gallen | IBS - Irritable Bowel Syndrome | OTHER: Low Lactose Diet|OTHER: Low FODMAP Diet | Details |
| NCT01286597 | The Effects of Lactose Intolerance on Gastrointestinal Function and Symptoms in a Chinese Population | NA | UNKNOWN | Sir Run Run Shaw Hospital | Lactose Intolerance|Irritable Bowel Syndrome | DIETARY_SUPPLEMENT: dietary restriction | Details |
| NCT00403923 | Amount of Lactose Causing Symptoms in People With Lactose Intolerance and Ulcerative Colitis | NULL | COMPLETED | University Hospitals, Leicester | Lactose Intolerance|Ulcerative Colitis | DIETARY_SUPPLEMENT: Lactose in water | Details |
| NCT06541938 | AIRE-2 Device for Study of Breath Analysis in IBD | NA | RECRUITING | McMaster University | Inflammatory Bowel Diseases | DIETARY_SUPPLEMENT: low FODMAP diet|DIETARY_SUPPL… | Details |
| CTRI/2024/01/061649 | Prevalence and impact of sarcopenia and frailty in inflammatory bowel disease, and the effect of multi-modal interventions on sarcopenia and clinical outcomes in patients with inflammatory bowel disease - NIL | PHASE3 | Not Recruiting | All India Institute of Medical Sciences | Health Condition 1: K509- Crohns disease, unspeci… | Intervention1: High protein anti-inflammatory die… | Details |
| NCT03863886 | Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis | NA | UNKNOWN | Carilion Clinic | Crohn Disease|Ulcerative Colitis | PROCEDURE: Endoscopic ultrasound catheter (UM-2R/… | Details |
| NCT00820365 | SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease | PHASE2 | COMPLETED | 4SC AG | Inflammatory Bowel Disease (IBD) | DRUG: SC12267 (4SC-101) | Details |
| NCT05668013 | A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | PHASE2 | ACTIVE_NOT_RECRUITING | Teva Branded Pharmaceutical Products R&D LLC | Crohn Disease|Colitis, Ulcerative | DRUG: TEV-48574 Dose Regimen A|DRUG: TEV-48574 Do… | Details |
| NCT07168434 | Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome | PHASE3 | RECRUITING | Biocodex | IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… | DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… | Details |
| NCT05588843 | Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Sanofi | Colitis Ulcerative | DRUG: SAR443122|DRUG: Placebo | Details |
| NCT05575505 | Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis. | PHASE2 | RECRUITING | Tanta University | Inflammatory Bowel Diseases | DRUG: Pentoxifylline 400 MG | Details |
| NCT05558761 | Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis | PHASE2 | COMPLETED | Tanta University | Inflammatory Bowel Diseases | DRUG: Pentoxifylline 400 MG | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
2'-Fucosyllactose Modulates the Intestinal Immune Response to Gut Microbiota an…
PMID: 40501496
Year: 2025
Relationship Type:
Mechanism
Score: 9.5
Inflammatory bowel disease (IBD), a recurrent gastrointestinal disease, is characterized by dysbiosis and inflammation. 2'-fucosyllactose (2'-FL) sho…
2'-Fucosyllactose restores the intestinal mucosal barrier in ulcerative colitis…
PMID: 38150914
Year: 2024
Relationship Type:
Mechanism
Score: 9.5
BACKGROUND & AIMS: 2'-Fucosyllactose (2'-FL), the primary constituent of human milk oligosaccharides, has been identified as a potential regulator of…
2'-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier…
PMID: 37111064
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the inte…
2'-Fucosyllactose Ameliorates Inflammatory Bowel Disease by Modulating Gut Micr…
PMID: 35252301
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Gut microbiota dysbiosis, together with goblet cells dysfunction has been observed in ulcerative colitis cases. This study aims to evaluate the poten…
2'-Fucosyllactose Promotes Colonization of Akkermansia muciniphila and Prevents…
PMID: 38393978
Year: 2024
Relationship Type:
Association
Score: 6.5
Impact of 2'-Fucosyllactose on Gut Microbiota Composition in Adults with Chroni…
PMID: 33799455
Year: 2021
Relationship Type:
Clinical Trial
Score: 6.5